Advanced Solid TumorPhase 1NCT04649385
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
A Phase 1 study testing BGB-15025, Tislelizumab and Carboplatin in people with Advanced Solid Tumor, run by BeiGene at 20 sites in 5 countries.
Trial summary
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Solid Tumor
- What is being tested?
- BGB-15025, Tislelizumab and Carboplatin
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 157 participants
- Where
- 20 sitesin 5 countries
- Study dates
- 4 Mar 2021to 15 May 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Phase 1a (dose escalation): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available, not tolerated or refused, and who have not received prior therapy targeting HPK1
- Phase 1b (dose expansion): Participant with histologically or cytologically confirmed advanced, and metastatic including non-small cell lung cancer, and gastric/Gastroesophageal junction cancer that have no prior systemic treatment for advanced disease and esophageal squamous cancer who have progressed following systemic anticancer therapies
- At least 1 measurable lesion as defined per RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
- Adequate organ function as indicated by the following laboratory values up to first dose of study treatment: Hemoglobin≥ 90 g/L, Absolute neutrophil count ≥ 1.5 x 10^9/L , Serum total bilirubin ≤ 1.5 x ULN (< 3 x ULN for participants with Gilbert syndrome ), AST and ALT≤ 2.5 x ULN
Who cannot join
- Active leptomeningeal disease or uncontrolled and untreated brain metastasis.
- Active autoimmune diseases or history of autoimmune diseases that may relapse
- Any active malignancy ≤ 2 years before the first dose of study treatment except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
- Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study treatment
- History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.
- For Cohort A: Known actionable mutations (including but not limited to epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, RET, MET, and ROS1, for which a targeted therapy has been approved by the local health authority and available.
- For Cohort B: Diagnosed with G/GEJ adenocarcinoma with positive HER2 status
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
20 sites in 5 countries.
20 sites in 5 countries
China7 sites
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060
Henan Cancer Hospital
Zhengzhou, Henan, 450000
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052
South Korea5 sites
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, 06351
The Catholic University of Korea, Seoul St Marys Hospital
SeochoGu, Seoul Teugbyeolsi, 06591
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, 03722
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, 05505
Australia4 sites
Peter Maccallum Cancer Centre
Melbourne, Victoria, VIC 3000
Linear Clinical Research
Nedlands, Western Australia, WA 6009
Prince of Wales Hospital
Randwick, New South Wales, NSW 2031
Ashford Cancer Centre Research Northeast
Windsor Gardens, South Australia, SA 5087
United States3 sites
The University of Texas Md Anderson Cancer Center
Houston, Texas, 77030-4009
Icahn School of Medicine At Mount Sinai
New York, New York, 10029-6504
Ut Health San Antonio Mays Cancer Center
San Antonio, Texas, 78229-4427
About this study
Official title: A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumor
- Being tested
- BGB-15025, Tislelizumab, Carboplatin, Cisplatin, Pemetrexed
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BGB-15025Drug
Administered orally once or twice daily (QD or BID)
TislelizumabDrug
Also called BGB-A317
Administered 200 mg intravenous (IV) infusion
CarboplatinDrug
Administered intravenously
CisplatinDrug
Administered intravenously
PemetrexedDrug
Administered intravenously
OxaliplatinDrug
Administered intravenously
CapecitabineDrug
Administered intravenously
PaclitaxelDrug
Administered intravenously
nab-paclitaxelDrug
Administered intravenously
| Study group | Role | What they receive |
|---|---|---|
| Phase 1a: Dose Escalation | Experimental | Part A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 7 increasing doses
Part B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy ) Receives: Drug: BGB-15025; Drug: Tislelizumab |
| Phase 1b: Dose Expansion | Experimental | Phase 1b dose expansion will begin based upon the recommended doses for expansion (RDFE) for BGB-15025 alone or in combination with tislelizumab, and with or without chemotherapy as determined from Phase 1a Receives: Drug: BGB-15025; Drug: Tislelizumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Paclitaxel; Drug: nab-paclitaxel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase 1a: Number of participants with dose limiting toxicities (DLTs)
Participants will be considered evaluable for DLTs if they 1) received ≥ 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.
Measured: Up to 3 Years
Phase 1a: Number of Participants Experiencing Adverse Events (AEs)
Measured: Up to 4 Years
Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)
Measured: Up to 4 years
The maximum tolerated dose (MTD) of BGB-15025
The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%
Measured: Up to 3 Years
Recommended Doses for Expansion (RDFE) of BGB-15025 monotherapy
The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%
Measured: Up to 3 years
RDFE of BGB-15025 in combination with tislelizumab
The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%
Measured: Up to 3 years
Phase 1b: Overall Response Rate (ORR) as assessed by the investigator
Measured: Up to 2 years
Secondary outcomes (18)
Phase 1a: Overall Response Rate (ORR) as assessed by the investigator
Measured: Up to 3 years
Duration Of Response (DOR) as assessed by the investigator
Measured: Up to 3 years
Disease Control Rate (DCR) as assessed by the investigator
Measured: Up to 3 years
Phase 1a: Maximum observed plasma concentration (Cmax) of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1a: Minimum observed plasma concentration (Cmin) of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1a: Time to maximum plasma concentration (Tmax) of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1a: Half-life of (t1/2) of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1a: Area under the concentration-time curve (AUC) of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1a: Apparent clearance (CL/F) of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1a: Apparent volume of distribution (Vz/F) of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1a: Accumulation Ratio for Cmax of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1a: Accumulation Ratio for AUC of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1a: Metabolite to parent ratio for BGB-15025 and its metabolite
Measured: Predose up to 8 hours postdose
Phase 1b: Number of Participants Experiencing Adverse Events (AEs)
Measured: Up to 3 years
Phase 1b: Number of Participants Experiencing Serious Adverse Events (SAEs)
Measured: Up to 3 years
Phase 1b: Plasma Concentrations of BGB-15025
Measured: Predose up to 8 hours postdose
Phase 1b: Plasma Concentrations of the metabolite
Measured: Predose up to 8 hours postdose
Phase 1b: Number of participants with dose limiting toxicities (DLTs)
Participants will be considered evaluable for DLTs if they 1) received ≥ 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.
Measured: Up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2020
- Study start4 Mar 2021
- Primary completion17 Oct 2025
- Study completion15 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Solid TumorStudies of the same condition, open and under way.
- More trials run by BeiGeneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 157 participants (actual)
Sponsor and investigators
- Lead sponsor
- BeiGene
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04649385
- Sponsor's protocol ID
- BGB-A317-15025-101
- Other IDs
- CTR20212721
- Status last verified
- Jun 2026
- First submitted
- 25 Nov 2020
- Last updated
- 26 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
- ClinicalTrials.gov ID
- NCT04649385
- Acronym / sponsor ID
- BGB-A317-15025-101
- Conditions
- Advanced Solid Tumor
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 157 participants (actual)
- Lead sponsor
- BeiGeneIndustry (pharma, biotech, devices)
- Study start
- 4 Mar 2021 (actual)
- Primary completion
- 17 Oct 2025 (actual)
- Study completion
- 15 May 2026 (actual)
- First posted
- 2 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Phase 1a: Dose Escalation | Experimental | Drug: BGB-15025, Drug: TislelizumabPart A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 7 increasing doses Part B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy ) |
| Phase 1b: Dose Expansion | Experimental | Drug: BGB-15025, Drug: Tislelizumab, Drug: Carboplatin, Drug: Cisplatin, Drug: Pemetrexed, Drug: Oxaliplatin, Drug: Capecitabine, Drug: Paclitaxel, Drug: nab-paclitaxelPhase 1b dose expansion will begin based upon the recommended doses for expansion (RDFE) for BGB-15025 alone or in combination with tislelizumab, and with or without chemotherapy as determined from Phase 1a |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Phase 1a (dose escalation): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available, not tolerated or refused, and who have not received prior therapy targeting HPK1
- Phase 1b (dose expansion): Participant with histologically or cytologically confirmed advanced, and metastatic including non-small cell lung cancer, and gastric/Gastroesophageal junction cancer that have no prior systemic treatment for advanced disease and esophageal squamous cancer who have progressed following systemic anticancer therapies
- At least 1 measurable lesion as defined per RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
- Adequate organ function as indicated by the following laboratory values up to first dose of study treatment: Hemoglobin≥ 90 g/L, Absolute neutrophil count ≥ 1.5 x 10^9/L , Serum total bilirubin ≤ 1.5 x ULN (< 3 x ULN for participants with Gilbert syndrome ), AST and ALT≤ 2.5 x ULN
Key exclusion criteria (8 listed)
- Active leptomeningeal disease or uncontrolled and untreated brain metastasis.
- Active autoimmune diseases or history of autoimmune diseases that may relapse
- Any active malignancy ≤ 2 years before the first dose of study treatment except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
- Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study treatment
- History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BGB-15025Administered orally once or twice daily (QD or BID) | Drug | Phase 1a: Dose Escalation, Phase 1b: Dose Expansion |
| TislelizumabAlso: BGB-A317Administered 200 mg intravenous (IV) infusion | Drug | Phase 1a: Dose Escalation, Phase 1b: Dose Expansion |
| CarboplatinAdministered intravenously | Drug | Phase 1b: Dose Expansion |
| CisplatinAdministered intravenously | Drug | Phase 1b: Dose Expansion |
| PemetrexedAdministered intravenously | Drug | Phase 1b: Dose Expansion |
| OxaliplatinAdministered intravenously | Drug | Phase 1b: Dose Expansion |
| CapecitabineAdministered intravenously | Drug | Phase 1b: Dose Expansion |
| PaclitaxelAdministered intravenously | Drug | Phase 1b: Dose Expansion |
| nab-paclitaxelAdministered intravenously | Drug | Phase 1b: Dose Expansion |
Primary outcome
Phase 1a: Number of participants with dose limiting toxicities (DLTs)
Time frame: Up to 3 Years
Participants will be considered evaluable for DLTs if they 1) received ≥ 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.
Phase 1a: Number of Participants Experiencing Adverse Events (AEs)
Time frame: Up to 4 Years
Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)
Time frame: Up to 4 years
The maximum tolerated dose (MTD) of BGB-15025
Time frame: Up to 3 Years
The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%
Recommended Doses for Expansion (RDFE) of BGB-15025 monotherapy
Time frame: Up to 3 years
The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%
RDFE of BGB-15025 in combination with tislelizumab
Time frame: Up to 3 years
The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%
Phase 1b: Overall Response Rate (ORR) as assessed by the investigator
Time frame: Up to 2 years
18 secondary outcomes
Phase 1a: Overall Response Rate (ORR) as assessed by the investigator
Time frame: Up to 3 years
Duration Of Response (DOR) as assessed by the investigator
Time frame: Up to 3 years
Disease Control Rate (DCR) as assessed by the investigator
Time frame: Up to 3 years
Phase 1a: Maximum observed plasma concentration (Cmax) of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1a: Minimum observed plasma concentration (Cmin) of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1a: Time to maximum plasma concentration (Tmax) of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1a: Half-life of (t1/2) of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1a: Area under the concentration-time curve (AUC) of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1a: Apparent clearance (CL/F) of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1a: Apparent volume of distribution (Vz/F) of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1a: Accumulation Ratio for Cmax of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1a: Accumulation Ratio for AUC of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1a: Metabolite to parent ratio for BGB-15025 and its metabolite
Time frame: Predose up to 8 hours postdose
Phase 1b: Number of Participants Experiencing Adverse Events (AEs)
Time frame: Up to 3 years
Phase 1b: Number of Participants Experiencing Serious Adverse Events (SAEs)
Time frame: Up to 3 years
Phase 1b: Plasma Concentrations of BGB-15025
Time frame: Predose up to 8 hours postdose
Phase 1b: Plasma Concentrations of the metabolite
Time frame: Predose up to 8 hours postdose
Phase 1b: Number of participants with dose limiting toxicities (DLTs)
Time frame: Up to 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2026.
- Individual participant dataSharing planned: Yes. BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Related trials for Advanced Solid Tumor
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Active, not recruitingPhase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Advanced Solid Tumor
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
20 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing BGB-15025, Tislelizumab and Carboplatin in people with Advanced Solid Tumor, run by BeiGene at 20 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in China, South Korea, Australia, United States, New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase 1a: Number of participants with dose limiting toxicities (DLTs) (time frame: Up to 3 Years). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026; AzTrials last refreshed its copy on 7 Nov 2026.